Lumos Pharma Inc. Stock News

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Lumos Pharma Inc (LUMO) shares closed today at 1.3% above its 52 week low of $6.80, giving the company a market cap of $59M. The stock is currently up 2.0% year-to-date, down 68.1% over the past 12 months, and down 46.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 63.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 9.2% The company's stock price performance over the past 12 months lags the peer average by 384.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company wil

The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2021 Results - Earnings Call Transcript

AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2021 Results - Earnings Call Transcript

AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D.,

Lumos Pharma Inc (NASDAQ: LUMO) expects 6-month primary outcome data from Phase 2 OraGrowtH210 Trial of LUM-201 in the 2H of 2023, citing the pace of site initiation and slower than anticipated en

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q1 2021 Results - Earnings Call Transcript

AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET

Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues Data show greater GH response in pediatric growth hormone deficiency (PGHD) from